# Efficacy & Safety of SCH 900435 in Schizophrenia (Study P06079)(WITHDRAWN)

> **NCT00988728** · PHASE2 · WITHDRAWN · sponsor: **Merck Sharp & Dohme LLC**

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** SCH 900435 (Org 25935)
- **DRUG:** Placebo
- **DRUG:** Olanzapine

## Key facts

- **NCT ID:** NCT00988728
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2011-02
- **Primary completion:** 2012-07
- **Final completion:** 2012-07
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2015-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00988728

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00988728, "Efficacy & Safety of SCH 900435 in Schizophrenia (Study P06079)(WITHDRAWN)". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT00988728. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*